BI-3802-Induced Polymerization Triggers Degradation of BCL6
PROTAC has been developed to degrade a wide range of clinically relevant targets. These small-molecule degraders engage both the E3 ligase and the target protein to promote the formation of a substrate–drug–ligase ternary complex. Although degraders can show notable efficacy and sustained depletion of targets, some proteins are resistant....
CCT369260 is an Orally Avtive B-cell Lymphoma 6 (BCL6) Inhibitor with Anti-Tumor Activity
BCL6 (B-cell lymphoma 6 protein) is a transcriptional repressor. Strikingly, this protein plays a key role in the formation and maintenance of germinal centers during the process of antibody affinity maturation. In addition, BCL6 represses genes involved in cell death, differentiation, and the DNA damage response. Most B-cell lymphomas...
F1324 is a High Affinity BCL6 Peptidic Inhibitor
B cell lymphoma 6 (BCL6) is a transcriptional repressor that interacts with its corepressors BcoR and SMRT. Since this protein-protein interaction (PPI) induces activation and differentiation of B lymphocytes, BCL6 is an attractive drug target for potential autoimmune disease treatments. In addition, BCL6 acts as a master regulator of...